Related Experiment Videos
[Pharmacokinetics and clinical studies on cefsulodin in neonates]
Insights
Cefsulodin (CFS) shows promising activity against Pseudomonas aeruginosa in neonates, similar to gentamicin. Pharmacokinetic studies reveal a favorable half-life, and clinical trials indicate effectiveness with no observed side effects.
Area of Science:
- Neonatal Pharmacology
- Infectious Diseases
- Antibiotic Research
Background:
- Pseudomonas aeruginosa is a significant pathogen in neonatal infections.
- Limited pharmacokinetic and efficacy data exist for cefsulodin (CFS) in neonates.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of cefsulodin in neonates.
- To compare the in vitro activity of cefsulodin against gentamicin and sulbenicillin.
Main Methods:
- Minimum inhibitory concentrations (MICs) were determined for 7 Pseudomonas aeruginosa strains.
- Pharmacokinetic analysis of cefsulodin following intravenous administration in a neonate.
- Clinical assessment of cefsulodin in three neonates.
Main Results:
- Cefsulodin demonstrated in vitro activity comparable to gentamicin against Pseudomonas aeruginosa.
- Intravenous cefsulodin in a neonate showed a half-life of 2.5 hours.
- Clinical efficacy was observed in 2 out of 3 neonates, with no adverse effects or laboratory abnormalities.
Conclusions:
- Cefsulodin exhibits favorable pharmacokinetics and clinical efficacy in neonates.
- Cefsulodin is a potential therapeutic option for neonatal Pseudomonas aeruginosa infections.
- Further studies are warranted to confirm safety and efficacy in a larger neonatal population.
Abstract:
Pharmacokinetics and clinical studies on cefsulodin (CFS) were conducted in neonates. 1. MIC's of CFS, sulbenicillin and gentamicin (GM) were determined using 7 strains of Pseudomonas aeruginosa clinically isolated from neonates and maintained as stock cultures. CFS was found to be nearly as active as GM. 2. When CFS 20 mg/kg was administered to a 12-day-old neonate by intravenous bolus injection, serum concentrations were 8.7 micrograms/ml before administration and 51.7 micrograms/ml at 30 minutes, 44.4 micrograms/ml at 1 hour, 38.6 micrograms/ml at 2 hours and 11.1 micrograms/ml at 6 hours after administration. The half-life was 2.5 hours. 3. CFS was administered alone or combination with other drugs to 3 neonates. The drug was clinically effective in 2 cases and slightly effective in another. Bacteriologically, one case was rated as decreased, another as replaced, and the remaining one as unchanged. 4. Neither side effects nor abnormal laboratory values attributable to CFS were found.